bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital
Written by Emily J. Thompson, Senior Investment Analyst
Source: Yahoo Finance
Acquisition Details: The Carlyle Group and SK Capital Partners, alongside Beacon Parent Holdings, have completed a tender offer to acquire bluebird bio, Inc. for $3.00 per share plus a contingent value right or $5.00 in cash, with the merger expected to finalize on June 2, 2025.
Company Challenges and Regulatory Approval: Bluebird bio faced significant financial challenges, including a high debt-to-capital ratio and low current ratio, but secured necessary regulatory approvals from the EU, China, and Turkey for the acquisition, which will proceed without a stockholder vote.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
